Abarceo attends ATTD conference
From 11–14 March in Barcelona, Abarceo promotes its diabetes drug restoring insulin secretion, improving sensitivity via daily oral pill.
See the latest news and media coverage for Abarceo Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Pre-clinical biotech developing mitochondrial dysfunction therapies
abarceo.comLast updated
In short: Abarceo Pharma presented data on its novel VDAC1 inhibitor treatment and engaged with investors to advance its mitochondrial repair therapies.
From 11–14 March in Barcelona, Abarceo promotes its diabetes drug restoring insulin secretion, improving sensitivity via daily oral pill.
They focus on Type 1 Diabetes and anticipate partnering and finance discussions at a Nordic meeting.
Groundbreaking data on VDAC1 inhibitors is revealed at the 5th Swedish Diabetes Summit via poster by Ruchi Jain and Claes Wollheim.
The company raises a total of 21.5 million kronor to develop drug candidates against type 2 diabetes.
Track Abarceo Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Abarceo Pharma and other trending companies.